Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

被引：1
|
作者：
Fakih, Marwan
Cleary, James M.
Hong, Yong Sang
Kim, Tae-You
Safyan, Rachael A.
Allen, Simon
Bailey, Lorna
Cha, Edward
Lenain, Christelle
Lu, Danny
Schulze, Jochen
Shemesh, Colby S.
Zimmermann, Stefan
机构：
[1] City Hope Comprehens Med Ctr, Duarte, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[10] Univ Hosp Lausanne, Immunooncol Serv, Dept Oncol, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study
    Saeed, Anwaar
    Tabernero, Josep
    Wang, Guan
    Ma, Xia
    Smith, Robina
    Hecht, J. Randolph
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS229 - TPS229
  • [42] CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial
    Saunders, M. P.
    Graham, J.
    Cunningham, D.
    Plummer, R.
    Church, D.
    Kerr, R.
    Cook, S.
    Zheng, S.
    La Thangue, N.
    Kerr, D.
    ESMO OPEN, 2022, 7 (06)
  • [43] Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)
    Oh, Do-Youn
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Lacy, Jill
    Lee, Jeeyun
    Macarulla, Teresa
    Manji, Gulam Abbas
    O'Reilly, Eileen Mary
    Allen, Simon
    Al-Sakaff, Nedal Jaffer Abdulla
    Barak, Hila
    Patel, Jilpa
    Pintoffl, Jan Peter
    Shemesh, Colby
    Zhang, Wei
    Zhang, Xiaosong
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] Randomized Phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIOKRK0110-study
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Graeven, U.
    Held, S.
    Stahler, A.
    Uhlig, J.
    Peuser, B.
    Freiberg-Richter, J.
    Denzlinger, C.
    Schwaner, I.
    Reddemann, C.
    Schuch, G.
    Schenk, M.
    Jung, A.
    Stintzing, S.
    Giessen-Jung, C.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 185 - 185
  • [45] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [46] Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
    Scheithauer, W.
    Prager, G.
    Greil, R.
    Mlineritsch, B.
    Schaberl-Moser, R.
    Gerger, A.
    Laengle, F.
    Viragos-Toth, I.
    Andel, J.
    Pichler, A.
    Pecherstorfer, M.
    Kretschmer, A.
    Seebacher, A.
    Jagdt, B.
    Eisterer, W.
    Krippl, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
    Fang, Xuefeng
    Zhu, Ning
    Zhong, Chenhan
    Wang, Liuhong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Li, Dan
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Wang, Zhanhuai
    Cao, Hongfeng
    Liao, Xiujun
    Yu, Ningjuan
    Xiao, Qian
    Mi, Mi
    Zhang, Suzhan
    Ding, Kefeng
    Yuan, Ying
    ECLINICALMEDICINE, 2023, 62
  • [48] Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    Kamei, Yutaro
    ONCOLOGY, 2020, 98 (09) : 637 - 642
  • [49] Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
    Fang, Xuefeng
    Zhong, Chenhan
    Weng, Shanshan
    Hu, Hanguang
    Wang, Jian
    Xiao, Qian
    Wang, Jianwei
    Sun, Lifeng
    Xu, Dong
    Liao, Xiujun
    Dong, Caixia
    Zhang, Suzhan
    Li, Jun
    Ding, Kefeng
    Yuan, Ying
    BMC CANCER, 2023, 23 (01)
  • [50] Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
    Xuefeng Fang
    Chenhan Zhong
    Shanshan Weng
    Hanguang Hu
    Jian Wang
    Qian Xiao
    Jianwei Wang
    Lifeng Sun
    Dong Xu
    Xiujun Liao
    Caixia Dong
    Suzhan Zhang
    Jun Li
    Kefeng Ding
    Ying Yuan
    BMC Cancer, 23
12345